KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Receivables - Net (2016 - 2026)

Gilead Sciences filings provide 17 years of Receivables - Net readings, the most recent being $4.9 billion for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 11.15% to $4.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 billion, a 11.15% increase, with the full-year FY2025 number at $4.9 billion, up 11.15% from a year prior.
  • Receivables - Net hit $4.9 billion in Q4 2025 for Gilead Sciences, down from $5.1 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $5.5 billion in Q1 2024 to a low of $3.9 billion in Q1 2021.
  • Median Receivables - Net over the past 5 years was $4.6 billion (2021), compared with a mean of $4.7 billion.
  • Biggest five-year swings in Receivables - Net: soared 32.58% in 2024 and later dropped 20.48% in 2025.
  • Gilead Sciences' Receivables - Net stood at $4.5 billion in 2021, then increased by 6.32% to $4.8 billion in 2022, then rose by 15.03% to $5.5 billion in 2023, then fell by 19.56% to $4.4 billion in 2024, then grew by 11.15% to $4.9 billion in 2025.
  • The last three reported values for Receivables - Net were $4.9 billion (Q4 2025), $5.1 billion (Q3 2025), and $4.8 billion (Q2 2025) per Business Quant data.